Product Information
ANORO ELLIPTA 62.5-25 MCG INH is a brand product labeled by GlaxoSmithKline LLC, priced at $7.7971 per EA under NDC 00173086910. Its NADAC has been published 637 times since Jul 23, 2014.
FDA first approved this application on Dec 18, 2013.
Strength
62.5; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173086910
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA203975FDA Approved
12/18/2013
On Market Since
1/31/2014
Pharmacological Classes
Price Statistics
The NADAC for ANORO ELLIPTA 62.5-25 MCG INH has been published 637 times since Jul 23, 2014, and over the history we have for it it has risen 75.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.7971 per EA |
|---|---|
| All-time high | $7.8208 (May 14, 2025) |
| All-time low | $4.4511 (Jul 23, 2014) |
| 52-week high | $7.8130 |
| 52-week low | $7.7971 |
| Median price | $6.7467 |
| Average price | $6.5439 |
| Largest weekly change | +8.0% (Jan 10, 2018) |
| Weeks tracked | 637 |
| Tracking since | Jul 23, 2014 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 36% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
umeclidinium bromide and vilanterol trifenatate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ANORO ELLIPTA 62.5-25 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for ANORO ELLIPTA 62.5-25 MCG INH, manufactured by GlaxoSmithKline LLC, is $7.7971 per EA (NDC 00173086910), effective Sep 30, 2026.
How has the price of ANORO ELLIPTA 62.5-25 MCG INH changed over time?
Over the history we have for it, the NADAC for ANORO ELLIPTA 62.5-25 MCG INH has risen 75.2%. It has been tracked across 637 weekly CMS publications since Jul 23, 2014.
What are the highest and lowest recorded NADAC prices for ANORO ELLIPTA 62.5-25 MCG INH?
Since Jul 23, 2014, the NADAC for ANORO ELLIPTA 62.5-25 MCG INH has ranged from a low of $4.4511 (Jul 23, 2014) to a high of $7.8208 (May 14, 2025), with a median of $6.7467 per EA.
Are there cheaper alternatives to ANORO ELLIPTA 62.5-25 MCG INH?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, UMECLIDINIUM-VILANTEROL ELLIPTA 62.5-25 MCG INH, is $4.9550 per EA — about 36% below ANORO ELLIPTA 62.5-25 MCG INH.
Who manufactures ANORO ELLIPTA 62.5-25 MCG INH?
ANORO ELLIPTA 62.5-25 MCG INH (NDC 00173086910) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.